GELATIN for Hepatocellular carcinoma: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 14 adverse event reports in the FDA FAERS database where GELATIN was used for Hepatocellular carcinoma.
Most Reported Side Effects for GELATIN
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Off label use | 35 | 28.9% | 4 | 2 |
| Device use issue | 22 | 18.2% | 4 | 0 |
| Post embolisation syndrome | 21 | 17.4% | 4 | 0 |
| Product use issue | 18 | 14.9% | 0 | 0 |
| Hepatic artery stenosis | 15 | 12.4% | 0 | 0 |
| Cholecystitis acute | 12 | 9.9% | 0 | 0 |
| Aspartate aminotransferase increased | 10 | 8.3% | 0 | 0 |
| Anaphylactic reaction | 9 | 7.4% | 0 | 3 |
| Drug hypersensitivity | 9 | 7.4% | 0 | 2 |
| Skin injury | 9 | 7.4% | 0 | 0 |
| Cough | 7 | 5.8% | 0 | 2 |
| Hypotension | 6 | 5.0% | 1 | 5 |
| Product use in unapproved indication | 6 | 5.0% | 1 | 3 |
| Abdominal injury | 5 | 4.1% | 0 | 0 |
| Alanine aminotransferase increased | 5 | 4.1% | 0 | 0 |
Other Indications for GELATIN
Transcatheter arterial chemoembolisation (36)
Therapeutic embolisation (23)
Product used for unknown indication (18)
Embolism (15)
Other Drugs Used for Hepatocellular carcinoma
ATEZOLIZUMAB (8,443)
BEVACIZUMAB (7,773)
LENVATINIB (5,384)
SORAFENIB (4,986)
CABOZANTINIB S-MALATE (2,670)
DURVALUMAB (1,255)
NIVOLUMAB (1,142)
REGORAFENIB (1,050)
TREMELIMUMAB\TREMELIMUMAB-ACTL (589)
PEMBROLIZUMAB (518)